|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
HPO |
|
|
|
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
MODY is genetically heterogeneous with five different genes identified to date: hepatocyte nuclear factor-4 alpha (HNF-4 alpha) [MODY1]; glucokinase [MODY2]; hepatocyte nuclear factor-1 alpha (HNF-1 alpha) [MODY3]; insulin promoter factor-1 (IPF-1) [MODY4]; and hepatocyte nuclear factor-1 beta (HNF-1 beta) [MODY5].
|
11058894 |
2000 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
MODY is both clinically and genetically heterogeneous, with six different genes identified to date; glucokinase (GCK), hepatocyte nuclear factor-1 alpha (HNF1A, or TCF1), hepatocyte nuclear factor-4 alpha (HNF4A), insulin promoter factor-1 (IPF1 or PDX1), hepatocyte nuclear factor-1 beta (HNF1B or TCF2), and neurogenic differentiation 1 (NEUROD1).
|
16917892 |
2006 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
MODY can result from mutations in at least six different genes encoding the glucose sensor enzyme glucokinase and transcription factors that participate in a regulatory network essential for adult beta-cell function.
|
18436708 |
2008 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
MODY was confirmed in 1,177 (35%) patients, with HNF1A (52%) and GCK mutations (32%) being most frequent in probands confirmed with MODY.
|
20499044 |
2010 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
Type 2 diabetes is a global problem, and current ineffective therapeutic strategies pave the way for novel treatments like small molecular activators targeting glucokinase (GCK).
|
21454522 |
2011 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
Maturity onset diabetes type 2 [MODY2 (#125851)] caused by mutations in the glucokinase gene (GCK).
|
29056535 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
MODY is genetically heterogeneous, associated with glucokinase mutations and a locus on chromosome 20q; in about 50% of cases, its genetic background is unknown.
|
7795649 |
1995 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
MODY due to mutations in the glucokinase gene is a relatively mild form of diabetes with mild fasting hyperglycemia and IGT in the majority.
|
8035658 |
1994 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
MODY is also linked to the glucokinase gene on chromosome 7p and many different mutations associated with MODY have been identified in this gene.
|
8894490 |
1996 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
MODY is genetically heterogeneous with three different genes identified to date; hepatocyte nuclear factor 4 alpha (HNF-4 alpha) [MODY1], glucokinase [MODY2] and hepatocyte nuclear factor 1 alpha (HNF-1 alpha) [MODY3].
|
9243109 |
1997 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
Glucokinase gene is genetic marker for NIDDM in American blacks.
|
1612198 |
1992 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Glucokinase gene mutation screening in Argentinean clinically characterized MODY patients.
|
19358091 |
2009 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Therapeutic
|
disease |
RGD |
Glucokinase activators (GKAs) are currently being developed as new therapies for type 2 diabetes and have been shown to enhance beta cell survival and proliferation in vitro.
|
22234649 |
2012 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
Glucokinase (GK) is a potential therapeutic target of type 2 diabetes and GK activators (GKAs) represent a promising class of small organic molecules which enhance GK activity.
|
28327441 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
Glucokinase activators (GKAs) are among the emerging drug candidates for the treatment of type 2 diabetes (T2D).
|
28390958 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM).
|
28800453 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
Glucokinase activators had been reported as one kind of new potential drugs for treatment of type 2 diabetes.
|
29477658 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
Biomarker
|
disease |
BEFREE |
GCK-MODY patients displayed increased and earlier glucagon responses during hypoglycemia compared with a group of glycemia-matched patients with type 2 diabetes.
|
30146176 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Glucokinase gene variations in Japanese-Americans with a family history of NIDDM.
|
7882822 |
1994 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Glucokinase mutations associated with non-insulin-dependent (type 2) diabetes mellitus have decreased enzymatic activity: implications for structure/function relationships.
|
8446612 |
1993 |